ImmunoGen Inc. (IMGN)
NASDAQ: IMGN
· Real-Time Price · USD
31.23
0.00 (0.00%)
At close: Feb 09, 2024, 9:58 PM
ImmunoGen Revenue Breakdown
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|
| License and milestone fees Revenue | 51K | 40K | 15.03M | 30.78M | 7.38M | 6.97M | 30.89M | 19.56M |
| License and milestone fees Revenue Growth | +27.50% | -99.73% | -51.17% | +316.96% | +5.87% | -77.43% | +57.90% | n/a |
| Non-cash royalty revenue related to the sale of future royalties Revenue | 7.36M | 5.74M | 4.84M | 7.72M | 7.99M | 7.12M | 6.43M | 8.04M |
| Non-cash royalty revenue related to the sale of future royalties Revenue Growth | +28.09% | +18.66% | -37.35% | -3.37% | +12.32% | +10.70% | -20.05% | n/a |
| Product revenue, net Revenue | 105.16M | 77.37M | 29.54M | 109K | n/a | 73K | 758K | 388K |
| Product revenue, net Revenue Growth | +35.92% | +161.88% | +27004.59% | n/a | -100.00% | -90.37% | +95.36% | n/a |
| Research and development support Revenue | 855K | n/a | 455K | n/a | n/a | n/a | n/a | n/a |
| Research and development support Revenue Growth | n/a | -100.00% | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 37.74M | 36.36M | 40.02M | 42.06M | 33.62M | 23.79M | 16.65M | 13.58M | 10.3M | 9.73M | 10.21M | 9.74M | 10.23M | 9.77M | 8.86M | 9.8M | 9.21M | 8.7M | 10.78M | 9.72M | 8.35M | 8.65M | 9.99M | 9.05M | 7.91M | 8.84M | 8.12M | 8.54M | 9.46M | 9.3M | 11.23M | 8.05M | 8.33M | 7.26M | 7M |
| Selling, General, and Administrative Revenue Growth | +3.82% | -9.15% | -4.87% | +25.11% | +41.31% | +42.92% | +22.61% | +31.86% | +5.85% | -4.71% | +4.84% | -4.82% | +4.75% | +10.19% | -9.58% | +6.46% | +5.84% | -19.28% | +10.86% | +16.47% | -3.53% | -13.44% | +10.47% | +14.42% | -10.50% | +8.83% | -4.89% | -9.76% | +1.73% | -17.24% | +39.50% | -3.30% | +14.71% | +3.73% | n/a |
| Research and Development Revenue | 47.57M | 50.08M | 51.62M | 58.48M | 59.18M | 51.42M | 44.28M | 48.97M | 33.15M | 34.59M | 34.41M | 39.58M | 24.68M | 22.92M | 27.41M | 26.05M | 21.02M | 28.56M | 38.89M | 43.11M | 47.24M | 38.7M | 44.83M | 39.84M | 31.69M | 35.32M | 32.89M | 33.66M | 32.91M | 37.49M | 36.09M | 38.2M | 35.13M | 30.44M | 25.67M |
| Research and Development Revenue Growth | -5.01% | -2.99% | -11.74% | -1.18% | +15.09% | +16.12% | -9.57% | +47.73% | -4.17% | +0.51% | -13.05% | +60.33% | +7.70% | -16.37% | +5.19% | +23.98% | -26.42% | -26.57% | -9.78% | -8.75% | +22.07% | -13.67% | +12.52% | +25.73% | -10.28% | +7.39% | -2.28% | +2.27% | -12.22% | +3.87% | -5.51% | +8.73% | +15.43% | +18.59% | n/a |